Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts
Monday, December 23, 2024

Tempus AI Inc. is a leader in the intersection of AI and precision medicine, offering significant potential for growth in 2025 and beyond

›
  Business/Investment Report on Tempus AI Inc. (TEM) - Class A Shares Overview Tempus AI Inc. (Ticker: TEM) is a technology-driven healthcar...
Thursday, November 14, 2024

Intellia Therapeutics has spent the past 10 years developing cutting edge genome editing technology to cure diseases

›
  A Business Report on: Intellia Therapeutics Executive Summary Intellia Therapeutics is a leading biotechnology company specializing in the...
Monday, September 23, 2024

IN treating Cancerous tumors, TransCode's technology is designed to target dysregulated microRNAs implicated in cancer progression, metastasis, and resistance to existing therapies.

›
  Investor Report: TransCode Therapeutics Inc. (NASDAQ: RNAZ) Introduction TransCode Therapeutics Inc. is a clinical-stage biopharmaceutical...
Thursday, July 25, 2024

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases

›
  One of their primary areas of development is in T-cell receptor (TCR) therapeutics. They have identified and characterized over 8,000 uniq...
Tuesday, July 2, 2024

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi

›
  On June 28th  Agenus Inc . ("Agenus") (Nasdaq: $AGEN), announced results from an investigator-sponsored trial (IST) of botensili...
Thursday, June 20, 2024

Illumina's strong market position in the genomics and life sciences sectors, positive return on equity, recent insider buying and Ai applications signal confidence in its future​

›
 Illumina Inc. (NASDAQ: ILMN), has several positive indicators for the company's prospects going forward. Analyst Ratings and Price Targ...
1 comment:
Friday, May 24, 2024

Editas Medicine and CRISPR Therapeutics are both gene-editing companies that focus on developing therapies using CRISPR-Cas9 technology.

›
    Let’s explore their differences and where they stand in terms of DNA editing technology: Editas Medicine : Market Cap : Approximately $4...